Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities

Hayman, Benoit; Bowles, Alex; Evans, Beth; Eyermann, Elizabeth; Nepomnyashchiy, Lyudmila; Pagliusi, Sonia

doi:10.1016/j.vaccine.2020.12.085

Cited by 9 publications

(7 citation statements)

References 16 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the high-cost and complexity of in-house development, often manufacturers engage in licensing agreements and joint ventures to access new technologies and expertise. Recent research has revealed that partnerships for novel and improved vaccines between DCVMN members is particularly low, with manufacturers electing to engage with biotechnology companies and academic institutions [19] . Our matching analysis, illustrated in Figure 3 , suggests that there are ample opportunities for ‘South-South’ collaborations.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective

Hayman

Suri

Prasad

2021

Vaccine

Self Cite

View full text Add to dashboard Cite

Vaccine manufacturers from developing countries have a proven track record of developing, producing, and supplying high-quality vaccines globally. However, due to the complexity of vaccine manufacturing, numerous stakeholder organizations support manufacturers across a variety of functions. To optimize the support from stakeholders it is instrumental to first understand which manufacturing processes these manufacturers require support for and what support functions are most beneficial. To this end, the Developing Countries Vaccine Manufacturers Network designed a comprehensive survey to assess the specific needs of the Network’s member organizations. We found that almost all sampled manufacturers are interested in obtaining funding or technology transfers for COVID-19 vaccines. Furthermore, results indicated that manufacturers have a strong appetite for modern technology platforms, particularly RNA technologies. Scale-up, phase III clinical trials, and formulation were also key processes for which manufacturers require support.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective

Hayman

Suri

Prasad

2021

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other political, economic, and social factors are also involved. These are illustrated in Hayman et al, Kraigsley et al, and Phillips et al [113][114][115]. Lowering the overall manufacturing costs is an essential requitement to help LMICs to become more independent.…”

Section: Some Economic Considerationsmentioning

confidence: 99%

“…Other political, economic, and social factors are also involved. These are illustrated in Hayman et al, Kraigsley et al, and Phillips et al [ 113 , 114 , 115 ].…”

Section: Some Economic Considerationsmentioning

confidence: 99%

Pichia pastoris (Komagataella phaffii) as a Cost-Effective Tool for Vaccine Production for Low- and Middle-Income Countries (LMICs)

Magalhaes

Keshavarz-Moore

2021

Bioengineering

View full text Add to dashboard Cite

Vaccination is of paramount importance to global health. With the advent of the more recent pandemics, the urgency to expand the range has become even more evident. However, the potential limited availability and affordability of vaccines to resource low- and middle-income countries has created a need for solutions that will ensure cost-effective vaccine production methods for these countries. Pichia pastoris (P. pastoris) (also known as Komagataella phaffii) is one of the most promising candidates for expression of heterologous proteins in vaccines development. It combines the speed and ease of highly efficient prokaryotic platforms with some key capabilities of mammalian systems, potentially reducing manufacturing costs. This review will examine the latest developments in P. pastoris from cell engineering and design to industrial production systems with focus on vaccine development and with reference to specific key case studies.

show abstract

“…Moreover, most vaccine manufacturers in these countries lack high-level technical expertise, which presents further challenges for gaining access to best practices and know-how. A recent study has shown that the number of LMICs that can currently translate shared key knowledge into production capacity is still a minority [25].…”

Section: International Efforts During the Covid-19 Pandemicsmentioning

confidence: 99%

International Efforts and Next Steps to Advance COVID-19 Vaccines Research and Production in Low- and Middle-Income Countries

Wang

Raposo

2021

Vaccines

View full text Add to dashboard Cite

Equitable and efficient distribution of COVID-19 vaccines continues to be a key issue in global health, and a targeted approach is needed to meet the World Health Organization’s world vaccination targets. Although some low- and middle-income countries (LMICs) are developing their own vaccines to address the distribution problem, legal and technical challenges have had a negative impact on productivity. This article explores relevant international legal instruments that can enable faster research and development of COVID-19 vaccines in LMICs, focusing on the role of biosafety standards, biological materials transfer, and key knowledge sharing. Our analysis has established that the potential of existing global health legal instruments has yet to be realized in order to close the productivity gap in LMICs and strengthen their vaccine manufacturing capacity. Additionally, mutual recognition of vaccine efficacy has become a new challenge for achieving global vaccination targets. We argue that the World Health Organization should continue its leading position by developing a more practical and targeted framework to help LMICs overcome challenges arising from technology transfer, knowledge sharing, and politics.

show abstract

Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities

Cited by 9 publications

References 16 publications

COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective

COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective

Pichia pastoris (Komagataella phaffii) as a Cost-Effective Tool for Vaccine Production for Low- and Middle-Income Countries (LMICs)

International Efforts and Next Steps to Advance COVID-19 Vaccines Research and Production in Low- and Middle-Income Countries

Contact Info

Product

Resources

About